Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Warts Overview 9 Therapeutics Development 10 Pipeline Products for Warts - Overview 10 Warts - Therapeutics under Development by Companies 11 Warts - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Warts - Products under Development by Companies 15 Warts - Companies Involved in Therapeutics Development 17 3M Drug Delivery Systems 17 Aclaris Therapeutics, Inc. 18 Agilvax, Inc. 19 Aviragen Therapeutics, Inc. 20 Biogenomics Limited 21 BioMAS Ltd. 22 Cytovation AS 23 Foamix Pharmaceuticals Ltd. 24 G&E Herbal Biotechnology Co., Ltd. 25 Laboratories Ojer Pharma S.L. 26 LEO Pharma A/S 27 Nielsen Biosciences, Inc. 28 Novan, Inc. 29 Novartis AG 30 Promius Pharma, LLC 31 RXi Pharmaceuticals Corporation 32 Tamir Biotechnology, Inc. 33 Verrica Pharmaceuticals Inc. 34 Zydus Cadila Healthcare Limited 35 Warts - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 (cervical cancer + genital warts) vaccine - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 (digoxin + furosemide) - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 854-A - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 AS-101 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 AX-03 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 BTA-074 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Candida Albicans Antigen - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 CyPep-1 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 DFD-05 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 diphencyprone - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 FIT-039 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 hydrogen peroxide - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 imiquimod - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 imiquimod SR - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 ingenol mebutate - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 interferon alfa-2b - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 LFX-453 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 omiganan pentahydrochloride - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 povidone iodine - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 PP-210 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 ranpirnase - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 SB-206 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 SRT-100 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 VP-100 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Warts - Dormant Projects 80 Warts - Discontinued Products 81 Warts - Product Development Milestones 82 Featured News & Press Releases 82 May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206 82 Dec 21, 2015: RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for Cutaneous Warts 82 Dec 07, 2015: Aclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment of Common Warts 83 Oct 26, 2012: South Africa, first to grant IP protection in anti-warts 83 Appendix 84 Methodology 84 Coverage 84 Secondary Research 84 Primary Research 84 Expert Panel Validation 84 Contact Us 84 Disclaimer 85

List of Tables Number of Products under Development for Warts, H2 2016 10 Number of Products under Development by Companies, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 (Contd..1) 16 Warts - Pipeline by 3M Drug Delivery Systems, H2 2016 17 Warts - Pipeline by Aclaris Therapeutics, Inc., H2 2016 18 Warts - Pipeline by Agilvax, Inc., H2 2016 19 Warts - Pipeline by Aviragen Therapeutics, Inc., H2 2016 20 Warts - Pipeline by Biogenomics Limited, H2 2016 21 Warts - Pipeline by BioMAS Ltd., H2 2016 22 Warts - Pipeline by Cytovation AS, H2 2016 23 Warts - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 24 Warts - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016 25 Warts - Pipeline by Laboratories Ojer Pharma S.L., H2 2016 26 Warts - Pipeline by LEO Pharma A/S, H2 2016 27 Warts - Pipeline by Nielsen Biosciences, Inc., H2 2016 28 Warts - Pipeline by Novan, Inc., H2 2016 29 Warts - Pipeline by Novartis AG, H2 2016 30 Warts - Pipeline by Promius Pharma, LLC, H2 2016 31 Warts - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 32 Warts - Pipeline by Tamir Biotechnology, Inc., H2 2016 33 Warts - Pipeline by Verrica Pharmaceuticals Inc., H2 2016 34 Warts - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 35 Assessment by Monotherapy Products, H2 2016 36 Assessment by Combination Products, H2 2016 37 Number of Products by Stage and Target, H2 2016 39 Number of Products by Stage and Mechanism of Action, H2 2016 41 Number of Products by Stage and Route of Administration, H2 2016 43 Number of Products by Stage and Molecule Type, H2 2016 45 Warts - Dormant Projects, H2 2016 80 Warts - Discontinued Products, H2 2016 81 List of Figures Number of Products under Development for Warts, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 14 Assessment by Monotherapy Products, H2 2016 36 Assessment by Combination Products, H2 2016 37 Number of Products by Top 10 Targets, H2 2016 38 Number of Products by Stage and Top 10 Targets, H2 2016 38 Number of Products by Top 10 Mechanism of Actions, H2 2016 40 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 40 Number of Products by Routes of Administration, H2 2016 42 Number of Products by Stage and Routes of Administration, H2 2016 42 Number of Products by Molecule Types, H2 2016 44 Number of Products by Stage and Molecule Types, H2 2016 44

3M Drug Delivery Systems Aclaris Therapeutics, Inc. Agilvax, Inc. Aviragen Therapeutics, Inc. Biogenomics Limited BioMAS Ltd. Cytovation AS Foamix Pharmaceuticals Ltd. G&E Herbal Biotechnology Co., Ltd. Laboratories Ojer Pharma S.L. LEO Pharma A/S Nielsen Biosciences, Inc. Novan, Inc. Novartis AG Promius Pharma, LLC RXi Pharmaceuticals Corporation Tamir Biotechnology, Inc. Verrica Pharmaceuticals Inc. Zydus Cadila Healthcare Limited